Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.
Mylan Pharmaceutical's Xulane is the first generic contraceptive transdermal patch to hit the market, marking another milestone for the delivery technology.
Researchers at the University of Texas at Arlington found that nanoparticles they were studying for radiation detection in the security arena could produce a toxic byproduct able to damage cancer cells.
One way of bypassing the immune system to deliver drugs to a tumor site is to use the immune system itself as a delivery mechanism. And now researchers have unexpectedly found that nanoparticle-encased drugs injected into mice entered immune cells called monocytes, which then carry the treatment to the correct site.
Researchers at Harvard University's Wyss Institute have developed "smart" nanoparticles out of DNA that act like a virus to bypass the immune system's defenses and deliver drugs to a tumor.
Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.
The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.
A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.
In an effort to localize the effects of anesthesia, researchers have turned to magnetic nanoparticles to target the delivery of ropivacaine in a proof-of-concept animal study.
At MIT, researchers have developed nanoparticles that can carry as many as three cancer drugs at a time in a precise ratio.
Pennsylvania wound-care specialist Alliqua pulled in $15 million from a private funding round and another $5.3 million from the exercise of warrants, giving the company a $20.3 million windfall overall.
As drug delivery becomes more and more dependent on nanotechnology for treatments such as chemotherapy, it's important that scientists in the field understand the implications of the tiny vehicles and what factors might play a part, for good or bad, in their delivery potential.
Researchers at the University at Buffalo have put the "pop" into drug delivery by releasing compounds from liposomes called nanoballoons that break open upon being hit with a laser.
Novaliq is beginning an early-stage study of its cyclosporin eye drop for dry eye syndrome. Although cylosporin is poorly soluble in water, Novaliq's platform allows for a clear solution as opposed to an emulsion, making it more suitable for delivering drugs in the eye.
DNA nanorobots that have proven their drug-delivering performance in early in vitro clinical trials have now demonstrated that they can do the same operations in a living cockroach.
Dartmouth researcher Jack Hoopes has demonstrated that magnetic nanoparticle hyperthermia could be a possible treatment for breast cancer, as he presented in a new preclinical study at the American Association for Cancer Research annual meeting in San Diego.
In a study presented at the American Association for Cancer Research in San Diego this week, researchers from the University of Colorado described a cancer-killing method that uses gold nanorods to target tumor cells in the bladder.
AstraZeneca has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline.
Researchers at the Italian Universtiy of Udine have developed small nanorobots with a "flap" designed to open and release compounds with unprecedented precision.
In a study published in the journal Nature Materials, University of Pennsylvania scientists describe a hydrogel they developed that is designed to be applied directly to heart muscle to reduce continuing damage after a heart attack.